Furthermore, resveratrol, which simultaneously inhibits the activation of PI3K/AKT and MEK/ERK pathways (resulting in activation of FOXO), could be an attractive candidate for the management of pancreatic cancer. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.